Randolph H Hastings1,2,3, Philippe R Montgrain4,5,6, Rick A Quintana4, Boris Chobrutskiy4, Ashkhan Davani4, Atsushi Miyanohara7, Sepi Mahooti8. 1. Anesthesiology Service, VA Medical Center (125), VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA, 92161, USA. rhhastings@ucsd.edu. 2. Research Service, VA San Diego Healthcare System, San Diego, USA. rhhastings@ucsd.edu. 3. Department of Anesthesiology, UC San Diego, San Diego, USA. rhhastings@ucsd.edu. 4. Research Service, VA San Diego Healthcare System, San Diego, USA. 5. Medicine Service, VA San Diego Healthcare System, San Diego, USA. 6. Department of Medicine, UC San Diego, San Diego, USA. 7. Viral Vector Core, UC San Diego, San Diego, USA. 8. Pathology Service, VA San Diego Healthcare System, San Diego, USA.
Abstract
PURPOSE: Expression of the carboxyl PTHrP region of parathyroid hormone-related protein (PTHrP) is a positive prognostic indicator in women with lung cancer, but amino PTHrP is a negative indicator in other lung cancer patients. This project investigated whether PTHrP could be expressed as predominantly amino PTHrP or carboxyl PTHrP in individual lung carcinomas. It also assessed domain-specific effects on cancer progression and patient survival. METHODS: PTHrP immunoreactivities were analyzed versus survival in a human lung cancer tissue microarray (TMA). Growth was compared in athymic mice for isogenic lung carcinoma xenografts differing in expression of amino and carboxyl PTHrP domains. RESULTS: In the TMA, 33 of 99 patient tumors expressed only one PTHrP domain, while 54 expressed both. By Cox regression, the hazard ratio for cancer-specific mortality (95% confidence interval) was 2.6 (1.28-5.44) for amino PTHrP (P = 0.008) and 0.6 (0-2.58) for carboxyl PTHrP (P = 0.092). Xenografts of H358 lung adenocarcinoma cells that overexpressed amino PTHrP grew twice as fast as isogenic low PTHrP tumors in athymic mice, but growth of tumors expressing amino plus carboxyl PTHrP was not significantly different than growth of the control tumors. In summary, the presence of amino PTHrP signifies worse prognosis in lung cancer patients. In mouse xenografts, this effect was abrogated if carboxyl PTHrP was also present. CONCLUSION: Amino PTHrP and carboxyl PTHrP can vary independently in different lung carcinomas. Carboxyl PTHrP may temper the stimulatory effect of amino PTHrP on cancer progression.
PURPOSE: Expression of the carboxyl PTHrP region of parathyroid hormone-related protein (PTHrP) is a positive prognostic indicator in women with lung cancer, but amino PTHrP is a negative indicator in other lung cancerpatients. This project investigated whether PTHrP could be expressed as predominantly amino PTHrP or carboxyl PTHrP in individual lung carcinomas. It also assessed domain-specific effects on cancer progression and patient survival. METHODS:PTHrP immunoreactivities were analyzed versus survival in a humanlung cancer tissue microarray (TMA). Growth was compared in athymic mice for isogenic lung carcinoma xenografts differing in expression of amino and carboxyl PTHrP domains. RESULTS: In the TMA, 33 of 99 patienttumors expressed only one PTHrP domain, while 54 expressed both. By Cox regression, the hazard ratio for cancer-specific mortality (95% confidence interval) was 2.6 (1.28-5.44) for amino PTHrP (P = 0.008) and 0.6 (0-2.58) for carboxyl PTHrP (P = 0.092). Xenografts of H358 lung adenocarcinoma cells that overexpressed amino PTHrP grew twice as fast as isogenic low PTHrPtumors in athymic mice, but growth of tumors expressing amino plus carboxyl PTHrP was not significantly different than growth of the control tumors. In summary, the presence of amino PTHrP signifies worse prognosis in lung cancerpatients. In mouse xenografts, this effect was abrogated if carboxyl PTHrP was also present. CONCLUSION: Amino PTHrP and carboxyl PTHrP can vary independently in different lung carcinomas. Carboxyl PTHrP may temper the stimulatory effect of amino PTHrP on cancer progression.
Entities:
Keywords:
Biochemical markers; Carcinoma, non-small cell lung; Molecular diagnosis and prognosis; Neuroendocrine and other endocrine factors; Oncogenes; Tumor suppressor proteins
Authors: Philippe R Montgrain; Leonard J Deftos; Douglas Arenberg; Ann Tipps; Rick Quintana; Shannon Carskadon; Randolph H Hastings Journal: Clin Lung Cancer Date: 2011-04-24 Impact factor: 4.785
Authors: J J Orloff; M B Ganz; M H Nathanson; M S Moyer; Y Kats; M Mitnick; A Behal; J Gasalla-Herraiz; C M Isales Journal: Endocrinology Date: 1996-12 Impact factor: 4.736
Authors: Serkan Kir; Hirotaka Komaba; Ana P Garcia; Konstantinos P Economopoulos; Wei Liu; Beate Lanske; Richard A Hodin; Bruce M Spiegelman Journal: Cell Metab Date: 2015-12-06 Impact factor: 27.287
Authors: Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin Journal: J Clin Oncol Date: 2003-09-02 Impact factor: 44.544
Authors: S Wu; C J Pirola; J Green; D T Yamaguchi; K Okano; H Jueppner; J S Forrester; J A Fagin; T L Clemens Journal: Endocrinology Date: 1993-12 Impact factor: 4.736
Authors: Awf A Al-Khan; Judith S Nimmo; Mourad Tayebi; Stewart D Ryan; James O Simcock; Raboola Tarzi; Charles A Kuntz; Eman S Saad; Michael J Day; Samantha J Richardson; Janine A Danks Journal: Sci Rep Date: 2020-01-31 Impact factor: 4.379